The commercial partnership brings the power of multi-parameter flow cytometry to molecular testing, improving workflow while delivering sensitive and highly reliable cell identification. IncellDx’s next generation (3Dx) investigational
The investment syndicate includes existing investors, including BlueWater Angels, and new investors RBV Capital, ExSight Capital, and Santen Pharmaceutical. Earlier in 2015, RetroSense Therapeutics closed a $7m Series
The Viaskin Milk patch is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that can deliver biologically active compounds to the immune system through intact skin without
The primary endpoint for the study is the incidence of amenorrhea induced by four months of treatment with two dose levels of Proellex compared to placebo. In addition,
The round was led by RiverVest Venture Partners, and included investments by New Enterprise Associates, BioMed Ventures and individual investors. Amplyx will use the funding to advance the
The open label trial is designed to evaluate the safety and efficacy of CMB305 in combination with atezolizumab versus atezolizumab alone in up to 80 patients with locally
RESTASIS is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, a type of
This novel supplement can be added to an optimized serum free media for greater protein yield or used as a culture media in place of FBS or other
Fera will initially focus on the signs and symptoms of osteoarthritis. The company aims to seek advice from the United States Food and Drug Administration with respect to
MRL Ventures, a venture fund of Merck, and JAFCO led the Series C preferred stock financing round. Brace Pharma Capital and MP Healthcare Venture Management were the other
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.